Abeona Therapeutics (ABEO) Gains from Sales and Divestitures (2022 - 2026)

Abeona Therapeutics' Gains from Sales and Divestitures history runs 5 years deep, the most recent figure standing at $913224.0 for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures rose 1239.69% year-over-year to $913224.0; the TTM figure through Mar 2026 stood at $913224.0 (up 1239.69% YoY), while the FY2025 annual figure was $1.5 million, up 44.88% from the prior year.
• Gains from Sales and Divestitures was $913224.0 for Q1 2026 at Abeona Therapeutics, down from $1.5 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.5 million in Q4 2025 to a low of $27526.0 in Q4 2022.
• Historically, Gains from Sales and Divestitures has averaged $680300.8 across 5 years, with a median of $818868.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Gains from Sales and Divestitures plunged 38.84% in 2025, then soared 1239.69% in 2026.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $27526.0 in 2022, then jumped by 882.89% to $270550.0 in 2023, then soared by 273.05% to $1.0 million in 2024, then soared by 44.88% to $1.5 million in 2025, then tumbled by 37.55% to $913224.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $913224.0 (Q1 2026), $1.5 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.